Discontinued — last reported Q3 '23
OLUMIANT Royalty Revenues — Royalties payable on net sales
Incyte OLUMIANT Royalty Revenues — Royalties payable on net sales decreased by 7.5% to $29.6M in Q3 2023 compared to the prior quarter. Year-over-year, this metric grew by 45.1%, from $20.4M to $29.6M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher values signal robust sales performance by the licensee, whereas lower values may reflect market saturation, patent expirations, or competitive pressures on the licensed product.
Detailed definition
This metric quantifies the specific royalty payments accrued or received based on the net sales performance of a license...
Peer comparison
Similar to royalty income metrics found in the financial disclosures of companies with significant out-licensing business models.
incy_segment_olumiant_royalty_revenues_royalties_payable_on_net_salesHistorical Data
| Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | |
|---|---|---|---|---|---|---|---|
| Value | $86.6M | $48.1M | $30.3M | $20.4M | $34.2M | $32M | $29.6M |
| QoQ Change | — | -44.5% | -37.0% | -32.7% | +67.6% | -6.4% | -7.5% |
| YoY Change | — | — | — | -76.4% | -28.9% | +5.6% | +45.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's olumiant royalty revenues — royalties payable on net sales?
- Incyte (INCY) reported olumiant royalty revenues — royalties payable on net sales of $29.6M in Q3 2023.
- How has Incyte's olumiant royalty revenues — royalties payable on net sales changed year-over-year?
- Incyte's olumiant royalty revenues — royalties payable on net sales increased by 45.1% year-over-year, from $20.4M to $29.6M.
- What does olumiant royalty revenues — royalties payable on net sales mean?
- The royalty payments earned by the company calculated as a percentage of the partner's net sales for a specific drug.